PBYI - Puma Biotechnology Inc Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
PumaBiotech (@pumabiotech) / X
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Articles about Puma Biotechnology | page 6
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology, Inc. (NASD:PBYI) Seasonal Chart | Equity Clock
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology NPS & Customer Reviews | Comparably
Puma Biotechnology Drug Granted Orphan Status - Los Angeles Business Journal
Puma Biotechnology, Inc. 2023 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology - Updates, News, Events, Signals & Triggers
Puma Biotechnology, Inc.
Here's What's Behind Puma's Crash | The Motley Fool
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | BioSpace
